![Mark Lewis: Version 9 of AJCC staging for GEP-NETs](https://oncodaily.com/pub/uploads/2024/05/IMG_2389-1280x872.jpeg)
Photo taken from acsjournals.onlinelibrary.wiley.com
May 2, 2024, 14:54
Mark Lewis: Version 9 of AJCC staging for GEP-NETs
Mark Lewis shared the following on X:
“JUST RELEASED!
Version 9 of American Joint Committee on Cancer (AJCC) staging for gastroenteropancreatic neuroendocrine tumors (GEP-NETs):
- Separates poorly differentiated NEC from grade 3 GEP-NETs.
- Recommends AGAINST checking chromogranin A.
- Includes endoscopic staging of T1NxM0.”
Additional information.
Source: Mark Lewis/X
Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.
AJCC
Alice C. Wei
Aman Chauhan
American Joint Committee on Cancer
Andrew M. Bellizzi
Arvind Dasari
Ayse T. Kendi
cancer
Chanjuan Shi
Chromogranin A
Daniel A. Anaya
Dermot O’Toole
Dhanpat Jain
Elliot A. Asare
Emily Bergsland
Erik Mittra
Gastroenteropancreatic Neuroendocrine Tumors
GEP-NETS
Guido Rindi
James Brierley
Kay Washington
Kelley Chan
Mark Lewis
MSHCT
OncoDaily
Oncology
Phillip S. Ge
Samantha M. Thomas
Sherlonda Flem
T1NxM0
Thomas A. Hope
Thorvardur R. Halfdanarson